HOME > TOP STORIES
TOP STORIES
-
BUSINESS Japan Ethical Drug Market Contracts 1% in Jan.-Mar.; Keytruda Top-Selling Drug for 8th Quarter Running: IQVIA
May 25, 2021
-
BUSINESS Janssen Seeks Japan Approval for COVID-19 Vaccine
May 24, 2021
-
REGULATORY MOF Panel’s Proposal Urges More Stringent Drug Cost Control, Revisiting of Semi-Automatic Listing
May 24, 2021
-
REGULATORY Biz Improvement Order Issued to 3 Codevelopers over Kobayashi Kako’s Fudged Data
May 24, 2021
-
REGULATORY PMDA Review Report: Flexible Discussions Needed for Eligibility of AstraZeneca Vaccine
May 24, 2021
-
ORGANIZATION JPMA Will Work towards Price Maintenance for On-Patent Medicines: New President
May 24, 2021
-
REGULATORY Japan Approves Moderna and AstraZeneca COVID-19 Vaccines
May 21, 2021
-
REGULATORY AstraZeneca, Moderna COVID-19 Vaccines in Line for Japan Approval on May 21
May 21, 2021
-
BUSINESS AbbVie Looks to Continue Double-Digit Annual Growth in New 5-Year Biz Plan
May 21, 2021
-
BUSINESS Janssen’s Darzquro, Chugai’s Polivy, JCR’s Izcargo Now Available in Japan
May 20, 2021
-
BUSINESS 5-Camp Battle Heating Up in HIF-PH Market; Evrenzo, Duvroq Neck-and-Neck for Top Spot
May 19, 2021
-
REGULATORY Pharma to Govt: Maintain Prices of Patented Drugs, It’s the Global Standard
May 18, 2021
-
REGULATORY AstraZeneca, Moderna COVID-19 Vaccines Up for Key Panel Review on May 20
May 17, 2021
-
BUSINESS Big 4 Wholesalers’ Operating Margin Sinks to 0.49% on COVID-19, Competition
May 17, 2021
-
BUSINESS 2 Ono Employees Admits Bribery Charges over Onoact Prescriptions
May 17, 2021
-
REGULATORY Japan, Pfizer Agree on 50 Million Extra Vaccine Doses by Sept-End
May 17, 2021
-
BUSINESS FY2020 Sales of 7 Major Japan Drug Makers Slip 2.7% on COVID-19, Price Woes: Tally
May 14, 2021
-
BUSINESS Ono Cuts Opdivo Guidance to 110 Billion Yen for FY2021
May 14, 2021
-
REGULATORY Pharma Groups Want Price Maintenance for Patented Meds, Payer Sees It “Natural” to Rectify Gap: Chuikyo
May 13, 2021
-
REGULATORY Chuikyo OKs Re-Pricing for Tecentriq, Vyndaqel; 3 I/O Peers Challenge Cuts in Vain
May 13, 2021
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
